#Sweden #Lund #Hansa Biopharma #IDEFIRIX #HNSA-5487

Hansa Biopharma's Q1 2025 Financial Results: A Strong Start to the Year

On April 24, 2025, Hansa Biopharma AB, a company listed on Nasdaq Stockholm under the ticker HNSA, released its interim financial report for the first quarter of 2025. The report highlighted robust growth and key advancements within the company’s product pipeline, positioning Hansa as a significant player in the biopharmaceutical sector.

Financial Overview

For Q1 2025, Hansa Biopharma reported total revenue of 66.3 million SEK, a notable increase of 39% from 47.4 million SEK in Q1 2024. The company’s product sales for IDEFIRIX®, a first-in-class immunoglobulin G-cleaving enzyme therapy, reached 65.7 million SEK, an impressive jump reflecting strong demand in the European market.

Chairman Peter Nicklin expressed optimism despite the unpredictability of the organ allocation market, which directly influences quarterly sales. He pointed out that the continued growth trajectory in revenues demonstrates the company’s resilience and commitment to enhancing patient care through innovative treatments.

Pipeline Progress

During the reported period, Hansa achieved significant milestones that are critical for its future growth. The company successfully completed enrollment in the Post Authorization Efficacy and Safety (PAES) study. This study is essential for maintaining IDEFIRIX's marketing authorization throughout Europe, with full readout results expected in the latter half of 2026.

Moreover, IDEFIRIX is seeing increased utilization in key European centers, which is expected to drive further growth. Hansa has successfully gained access and reimbursement for IDEFIRIX in three additional European markets, expanding the treatment's availability.

Nicklin also noted the notable results from the 15-HMedIdeS-09 Phase 2 study for Guillain-Barré Syndrome (GBS), indicating that the data has been prepared for oral presentation at an upcoming medical congress. This highlights the potential of IDEFIRIX to meet an unmet medical need in GBS.

Leadership Changes

In connection to its evolving strategy, Hansa announced the appointment of Renée Aguiar-Lucander as the new Chief Executive Officer, effective immediately. This change comes as Søren Tulstrup steps down from his CEO role, marking the end of a seven-year tenure.

Future Outlook

Looking ahead, Hansa expects several significant pipeline catalysts to emerge in the second half of 2025, including data releases from pivotal trials like the U.S. ConfIdeS Phase 3 trial in kidney transplantation and the anti-GBM Phase 3 pivotal trial. The company remains committed to developing its next-generation molecule, HNSA-5487, aimed at conditions such as myasthenia gravis, with recent positive interactions regarding its clinical development plan.

The financial summary laid out in the report also reflected increased operational focus:

• - Loss from operations: decreased to 93.4 million SEK from 159.4 million SEK in Q1 2024.
• - Net loss for the period: dropped significantly to 37.1 million SEK, showing improved expenditure control and operational efficiencies.

As a biopharmaceutical pioneer focusing on life-saving treatments for rare immunological conditions, Hansa Biopharma is poised for further advancements, backed by a solid financial performance. The company's innovation in the healthcare landscape, particularly with IDEFIRIX, illustrates a commitment to improving patient outcomes and addressing critical medical needs. For the latest updates, Hansa invites stakeholders to follow its journey through its investor relations channels.